Product Portfolio

7 WHO Essential Medicines serving 380 million people across the SADC region

Paracetamol Injection

Pain and Fever Management

Product Development

Adult formulations for effective pain relief and fever management in hospital settings.

Strength 500mg, 1000mg (1g)
Market Opportunity $450M SADC
Regulatory Status WHO PQ Pathway Initiated
Target Launch Q3 2027

Pediatric Paracetamol (UNIQUE)

Weight-Based Pediatric Formulation

Formulation Development

Innovative mg/kg weight-based dosing specifically designed for pediatric use with limited competition in region.

Strength mg/kg dosing
Market Opportunity $82M SADC
Regulatory Status WHO PQ Pathway Planned
Competitive Edge Limited Competition

Ceftriaxone Injection

Antibiotic for Bacterial Infections

Pre-Formulation Studies

Broad-spectrum antibiotic for treatment of bacterial infections in hospital and clinical settings.

Strength 1g, 2g
Market Opportunity $380M SADC
Regulatory Status WHO PQ Pathway Planned
Target Launch Q4 2027

Dexamethasone Injection

Anti-inflammatory & Immunosuppressant

Product Development

Essential corticosteroid for inflammatory conditions and immunosuppression.

Strength 4mg/ml
Market Opportunity $210M SADC
Regulatory Status National Registration Pathway
Target Launch 2028

Metoclopramide Injection

Anti-nausea & GI Motility

Pre-Formulation Studies

Treatment for nausea, vomiting, and gastrointestinal motility disorders.

Strength 10mg/2ml
Market Opportunity $145M SADC
Regulatory Status National Registration Pathway

Ranitidine Injection

GI Disorders & Ulcers

Formulation Screening

H2 receptor antagonist for treatment of gastrointestinal disorders and peptic ulcers.

Strength 50mg/2ml
Market Opportunity $168M SADC
Regulatory Status National Registration Pathway

Furosemide Injection

Diuretic for Heart Failure

Pre-Formulation Studies

Loop diuretic for treatment of edema, heart failure, and hypertension.

Strength 20mg/2ml
Market Opportunity $195M SADC
Regulatory Status National Registration Pathway

Regulatory Strategy

Phase 1 (2026-2027)

Mozambique Registration

  • MISAU approval for domestic market
  • GMP certification
  • Local market launch

Phase 2 (2027-2028)

SADC Expansion

  • Zimbabwe, Zambia, Malawi registrations
  • Regional distribution partnerships
  • Export capacity development

Phase 3 (2028-2030)

WHO Prequalification

  • International quality standards
  • UN and Global Fund procurement access
  • $500M+ market potential

Quality Standards

All products manufactured to WHO Good Manufacturing Practice (GMP) standards, ISO quality management systems, with stability and bioequivalence studies, under stringent regulatory oversight.

Manufacturing Capacity: 21.6 million vials annually at full capacity with flexible production lines, multi-product capability, and cold chain infrastructure.